1. Expert consensus on clinical application of 177Lu-prostate specific membrane antigen radio-ligand therapy in prostate cancer
- Author
-
Guobing LIU, Weihai ZHUO, Yushen GU, Zhi YANG, Yue CHEN, Wei FAN, Jianming GUO, Jian TAN, Xiaohua ZHU, Li HUO, Xiaoli LAN, Biao LI, Weibing MIAO, Shaoli SONG, Hao XU, Rong TIAN, Quanyong LUO, Feng WANG, Xuemei WANG, Aimin YANG, Dong DAI, Zhiyong DENG, Jinhua ZHAO, Xiaoliang CHEN, Yan FAN, Zairong GAO, Xingmin HAN, Ningyi JIANG, Anren KUANG, Yansong LIN, Fugeng LIU, Cen LOU, Xinhui SU, Lijun TANG, Hui WANG, Xinlu WANG, Fuzhou YANG, Hui YANG, Xinming ZHAO, Bo YANG, Xiaodong HUANG, Jiliang CHEN, Sijin LI, Jing WANG, Yaming LI, and Hongcheng SHI
- Subjects
177lu-prostate specific membrane antigen ,prostate cancer ,radio-ligand therapy ,expert consensus ,Medicine - Abstract
177Lu- prostate specific membrane antigen (PSMA) radio-ligand therapy has been approved abroad for advanced prostate cancer and has been in several clinical trials in China. Based on domestic clinical practice and experimental data and referred to international experience and viewpoints, the expert group forms a consensus on the clinical application of 177Lu-PSMA radio-ligand therapy in prostate cancer to guide clinical practice.
- Published
- 2024
- Full Text
- View/download PDF